Pacer Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,073,632
| Closed | -$41.6M | – | 3489 |
|
|
2025
Q1 | $41.6M | Buy |
1,073,632
+51,032
| +5% | +$1.87M | 0.1% | 184 |
|
|
2024
Q4 | $34.6M | Buy |
1,022,600
+246,923
| +32% | +$8.89M | 0.07% | 248 |
|
|
2024
Q3 | $31.7M | Buy |
775,677
+12,471
| +2% | +$510K | 0.07% | 268 |
|
|
2024
Q2 | $29.4M | Buy |
763,206
+193,811
| +34% | +$8.15M | 0.07% | 272 |
|
|
2024
Q1 | $24.4M | Buy |
569,395
+16,733
| +3% | +$690K | 0.06% | 291 |
|
|
2023
Q4 | $20.5M | Sell |
552,662
-22,320
| -4% | -$801K | 0.06% | 292 |
|
|
2023
Q3 | $20.8M | Buy |
574,982
+14,542
| +3% | +$516K | 0.08% | 235 |
|
|
2023
Q2 | $20M | Sell |
560,440
-462,202
| -45% | -$16.6M | 0.08% | 239 |
|
|
2023
Q1 | $36.4M | Buy |
1,022,642
+353,041
| +53% | +$12.4M | 0.16% | 130 |
|
|
2022
Q4 | $23.5M | Buy |
669,601
+363,617
| +119% | +$12.1M | 0.12% | 144 |
|
|
2022
Q3 | $9.01M | Buy |
305,984
+73,257
| +31% | +$2.78M | 0.06% | 265 |
|
|
2022
Q2 | $12.7M | Buy |
232,727
+135,053
| +138% | +$7.46M | 0.09% | 179 |
|
|
2022
Q1 | $5.32M | Buy |
97,674
+27,739
| +40% | +$1.51M | 0.04% | 413 |
|
|
2021
Q4 | $3.85M | Sell |
69,935
-5,921
| -8% | -$308K | 0.04% | 562 |
|
|
2021
Q3 | $3.62M | Sell |
75,856
-1,010
| -1% | -$50.7K | 0.05% | 520 |
|
|
2021
Q2 | $3.83M | Buy |
76,866
+6,323
| +9% | +$304K | 0.05% | 437 |
|
|
2021
Q1 | $3.15M | Sell |
70,543
-3,484
| -5% | -$158K | 0.05% | 392 |
|
|
2020
Q4 | $3.4M | Buy |
74,027
+1,046
| +1% | +$48K | 0.06% | 296 |
|
|
2020
Q3 | $3.43M | Buy |
72,981
+17,691
| +32% | +$886K | 0.07% | 221 |
|
|
2020
Q2 | $2.82M | Buy |
+55,290
| New | +$2.84M | 0.06% | 246 |
|
|
2020
Q1 | – | Sell |
-70,710
| Closed | -$4.15M | – | 857 |
|
|
2019
Q4 | $4.15M | Sell |
70,710
-23,085
| -25% | -$1.28M | 0.19% | 89 |
|
|
2019
Q3 | $5M | Buy |
93,795
+4,400
| +5% | +$226K | 0.11% | 176 |
|
|
2019
Q2 | $4.47M | Buy |
89,395
+5,405
| +6% | +$271K | 0.11% | 182 |
|
|
2019
Q1 | $4.39M | Buy |
83,990
+711
| +0.9% | +$35.5K | 0.12% | 147 |
|
|
2018
Q4 | $3.98M | Buy |
83,279
+7,132
| +9% | +$351K | 0.14% | 10 |
|
|
2018
Q3 | $3.82M | Buy |
76,147
+5,557
| +8% | +$282K | 0.14% | 127 |
|
|
2018
Q2 | $3.56M | Sell |
70,590
-6,561
| -9% | -$330K | 0.16% | 110 |
|
|
2018
Q1 | $3.77M | Buy |
77,151
+22,249
| +41% | +$1.04M | 0.21% | 74 |
|
|
2017
Q4 | $2.43M | Buy |
54,902
+20,404
| +59% | +$943K | 0.17% | 105 |
|
|
2017
Q3 | $1.75M | Buy |
34,498
+1,924
| +6% | +$97.6K | 0.16% | 97 |
|
|
2017
Q2 | $1.76M | Buy |
+32,574
| New | +$1.74M | 0.17% | 88 |
|
|
2013
Q4 | $905K | Buy |
+16,946
| New | +$1.1M | 0.22% | 135 |
|
Other funds holding GSK
JEST
Pacer Advisors's GSK Position: Q2 2025 in Review
Pacer Advisors sold out of GSK (GSK) in Q2 2025, closing a stake of 1,073,632 shares — an estimated $41.6M sold.
Pacer Advisors first reported a position in GSK in Q4 2013 and held it in 32 quarters. The position peaked at $41.6M in Q1 2025. 890 funds tracked by Wall St. Rank hold GSK as of Q2 2025.
- Pacer Advisors reported no remaining GSK position as of Q2 2025 after selling out during the quarter.
- Pacer Advisors sold 1,073,632 GSK shares in Q2 2025, an estimated $41.6M.
- Pacer Advisors first reported a position in GSK in Q4 2013 and held it in 32 quarters.
- Pacer Advisors's GSK position peaked at $41.6M in Q1 2025.
- 890 funds tracked by Wall St. Rank held GSK as of Q2 2025.
Based on Pacer Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.